Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing
Latest Information Update: 16 Feb 2024
At a glance
- Drugs Rituximab (Primary) ; Ocrelizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms OVERLORD-MS
- 30 Aug 2023 Planned End Date changed from 14 Feb 2025 to 14 May 2025.
- 30 Aug 2023 Planned primary completion date changed from 14 Feb 2025 to 14 May 2025.
- 30 Aug 2023 Status changed from recruiting to active, no longer recruiting.